Cargando…

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body

Colorectal cancer is the third leading cause of cancer-related deaths in the United States. Treatment of colorectal cancer remains a challenge to clinicians as well as drug developers. Irinotecan, a Camptothecin derivative, is successfully used for the treatment of this rapidly progressing malignanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Yingfang, Mansoor, Najia, Ahmad, Tasneem, Khan, Rafeeq Alam, Czejka, Martin, Sharib, Syed, Yang, Dong-Hua, Ahmed, Mansoor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564636/ https://www.ncbi.nlm.nih.gov/pubmed/28636998 http://dx.doi.org/10.18632/oncotarget.18380

Ejemplares similares

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002)

Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan in situ in the living body
por: Idili, Andrea, et al.
Publicado: (2019)

Systemic side effects of eye drops: a pharmacokinetic perspective
por: Farkouh, Andre, et al.
Publicado: (2016)

Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
por: Scheithauer, W., et al.
Publicado: (1993)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models
por: Yoshida, Kenta, et al.
Publicado: (2013)

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model
por: Gruber, Andrea, et al.
Publicado: (2018)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer
por: Brendel, Karl, et al.
Publicado: (2021)

Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model
por: Asami, Shun, et al.
Publicado: (2017)

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

Targeting MUCL1 protein inhibits cell proliferation and EMT by deregulating β-catenin and increases irinotecan sensitivity in colorectal cancer
por: Abdulla, Maha, et al.
Publicado: (2022)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug
por: Song, Shiwen, et al.
Publicado: (2023)

Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib
por: Dharani, Sathish, et al.
Publicado: (2022)

Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model
por: Lewis, Andrew L., et al.
Publicado: (2012)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine
por: He, Lixia, et al.
Publicado: (2022)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Disc Battery - An Unusual Vaginal Foreign Body in a Child
por: Khan, Yousuf Aziz, et al.
Publicado: (2016)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Risk factors for coronary heart disease in patients below 45 years of age
por: Nadeem, Mansoor, et al.
Publicado: (2013)

Hormone-Producing Tumours of the Gastrointestinal Tract - Contemporary Issues in Gastroenterolgy
por: Ahmed, Syed Rafeeq
Publicado: (1986)

A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver
por: Melancon, Marites P., et al.
Publicado: (2021)

Antihyperlipidemic effects of Citrus sinensis, Citrus paradisi, and their combinations
por: Mallick, Neelam, et al.
Publicado: (2016)

Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation
por: Yang, Wenqian, et al.
Publicado: (2019)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Foreign body aspiration in an adult: An endobronchial “Melon-oma”
por: Ul Haq, Irfan, et al.
Publicado: (2022)

Towards Reliable and Energy-Efficient Incremental Cooperative Communication for Wireless Body Area Networks
por: Yousaf, Sidrah, et al.
Publicado: (2016)

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor
por: Sparreboom, A, et al.
Publicado: (2004)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
por: Shen, Chaozhuang, et al.
Publicado: (2023)

A novel semi-supervised framework for UAV based crop/weed classification
por: Khan, Shahbaz, et al.
Publicado: (2021)

Iodine deficiency in children: A comparative study in two districts of south-interior Karnataka, India
por: Ahmed, Mansoor, et al.
Publicado: (2014)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury
por: Zaki, Almaz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cpjfa2q9noeagvjte5gij0m7ng